share_log

Panbela Therapeutics | POS AM: Post-effective amendment to a registration statement that is not immediately effective upon filing

SEC announcement ·  Mar 30 05:13
Summary by Futu AI
Panbela Therapeutics, Inc. filed a post-effective amendment to a Form S-1 registration statement with the Securities and Exchange Commission on March 29, 2024. The amendment pertains to the issuance of up to 8,750,000 shares of common stock underlying Class E and Class F common stock purchase warrants previously issued in a registered public offering. The shares are issuable upon exercise of the warrants at a price of $2.06 per share. The company's common stock is quoted on the OTC Pink Market under the symbol 'PBLA,' with the last reported sale price on March 26, 2024, being $0.64 per share. Panbela Therapeutics, a Delaware corporation with a primary standard industrial classification code number of 2834, is a clinical-stage biopharmaceutical company focused on developing treatments for patients with urgent unmet medical needs. The company's CEO is Jennifer K. Simpson, and its principal executive offices are located in Waconia, Minnesota. The proceeds from the exercise of the warrants are intended for the continued clinical development of Panbela's product candidates and for general corporate purposes.
Panbela Therapeutics, Inc. filed a post-effective amendment to a Form S-1 registration statement with the Securities and Exchange Commission on March 29, 2024. The amendment pertains to the issuance of up to 8,750,000 shares of common stock underlying Class E and Class F common stock purchase warrants previously issued in a registered public offering. The shares are issuable upon exercise of the warrants at a price of $2.06 per share. The company's common stock is quoted on the OTC Pink Market under the symbol 'PBLA,' with the last reported sale price on March 26, 2024, being $0.64 per share. Panbela Therapeutics, a Delaware corporation with a primary standard industrial classification code number of 2834, is a clinical-stage biopharmaceutical company focused on developing treatments for patients with urgent unmet medical needs. The company's CEO is Jennifer K. Simpson, and its principal executive offices are located in Waconia, Minnesota. The proceeds from the exercise of the warrants are intended for the continued clinical development of Panbela's product candidates and for general corporate purposes.
Helpful
Not Helpful

This announcement is a separate document:

Doc 1

Doc 2

The information provided by Futu AI is automatically generated by third-party artificial intelligence (AI) software based on news content. It is only available to users located outside of China mainland.


The above content is for informational or educational purposes only and does not constitute any investment advice related to Futu. Although we strive to ensure the truthfulness, accuracy, and originality of all such content, we cannot guarantee it.